Moneycontrol
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Aurobindo Pharma

Aurobindo Pharma

BSE: 524804|NSE: AUROPHARMA|ISIN: INE406A01037|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Jun 19, 16:00
609.30
-5.05 (-0.82%)
VOLUME 225,492
LIVE
NSE
Jun 19, 15:59
608.55
-5.3 (-0.86%)
VOLUME 3,328,100
News on Aurobindo Pharma
Select Year: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Nifty may retest downside support of 10,740; buy Aurobindo Pharma for the near term

8.57 am | 18 Jun 2018 |  Source: Moneycontrol.com

“The Nifty ended last week with an inverted hammer candle, which implies nervousness still persists” says Jaydeb Dey of Stewart & Mackertich Wealt...

Buy Aurobindo Pharma; target of Rs 1070: Centrum Research

3.30 pm | 13 Jun 2018 |  Source: Moneycontrol.com

Centrum Research is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1070 in its research report dated Ju...

Aurobindo Pharma shares jump over 4% on USFDA nod for heartburn drug

6.45 pm | 08 Jun 2018 |  Source: PTI

In terms of equity volume, 2.57 lakh shares of the company were traded on BSE and over 39 lakh shares changed hands at NSE during the day....

Aurobindo Pharma gets USFDA nod for heartburn drug

11.57 am | 08 Jun 2018 |  Source: PTI

"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Omeprazole Delayed-Release tablets OTC, 20mg....

Aurobindo Pharma gains 3% on USFDA approval for heartburn drug

11.25 am | 08 Jun 2018 |  Source: Moneycontrol.com

The said product will be launched in June 2018....

Sell Aurobindo Pharma, target Rs 485: Vinay Rajani

11.59 am | 05 Jun 2018 |  Source: Moneycontrol.com

We recommend selling Aurobindo Pharma for the downside target of Rs 485 with a stop loss placed at Rs 570....

2008 vs 2018: Why investors should be worried this time around

9.19 am | 05 Jun 2018 |  Source: Moneycontrol.com

The Nifty is trading above its 50, 100 and 200- daily moving average (DMA), indicating a bullish trend for the short to medium term....

Markets@Moneycontrol: Nifty likely to retest 10,600; 3 stocks which could give 6-9% return 

8.41 am | 05 Jun 2018 |  Source: Moneycontrol.com

Trends on SGX Nifty indicate a negative opening for the broader index in India, a fall of 20.5 points or 0.19 percent. Nifty futures were trading arou...

Buy or sell: Top stock trading ideas by market experts which are good short term bets

8.41 am | 05 Jun 2018 |  Source: Moneycontrol.com

Vinay Rajani of HDFC Securities is of the view that one can sell Aurobindo Pharma with target at Rs 485 and stop loss at Rs 570, a sell in Muthoot Fin...

Aurobindo Pharma stock falls 7% after Q4 earnings miss analyst expectations

11.39 am | 29 May 2018 |  Source: Moneycontrol.com

The US formulation business contributed 45 percent to the total revenue and grew 5.8 percent to Rs 1,738.8 crore due to new product launches....

Aurobindo Pharma Q4 net profit falls marginally to Rs 528.8 crore

8.41 pm | 28 May 2018 |  Source: Moneycontrol.com

Revenue from operations rose 11.2% to Rs 4,049.1 crore, compared to Rs 3,641.63 in the year ago period....

Buy Aurobindo Pharma; target of Rs 909: Prabhudas Lilladher

3.48 pm | 28 May 2018 |  Source: Moneycontrol.com

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 909 in its research report dated ...

Aurobindo Pharma Q4 preview: Profits to rise despite generic Renvela facing steep erosion, lack of approvals in US

3.30 pm | 28 May 2018 |  Source: Moneycontrol.com

A Reuters poll of analyst estimates forecasts net profit to gain to Rs 588.7 crore....

Crude oil, rupee, earnings to dictate market trend; these 10 stocks can give 28-94% returns

9.08 am | 22 May 2018 |  Source: Moneycontrol.com

Higher crude oil prices and the rupee’s weakness will continue to dampen sentiment putting pressure on the fiscal deficit and bond yields in the sho...

Aurobindo Pharma Q4 PAT seen up 10.7% YoY to Rs. 570 cr: HDFC Securities

1.01 pm | 20 Apr 2018 |  Source: Moneycontrol.com

Net Sales are expected to increase by 13.8 percent Y-o-Y (down 5.5 percent Q-o-Q) to Rs. 4,100 crore, according to HDFC Securities....

Aurobindo Q4 PAT seen up 25.3% YoY to Rs. 648.2 cr: Edelweiss

5.55 pm | 16 Apr 2018 |  Source: Moneycontrol.com

Net Sales are expected to increase by 19 percent Y-o-Y to Rs. 4,334.4 crore, according to Edelweiss....

Accumulate Aurobindo Pharma; target of Rs 728: Arihant Capital

8.01 pm | 11 Apr 2018 |  Source: Moneycontrol.com

Arihant Capital recommended accumulate rating on Aurobindo Pharma with a target price of Rs 728 in its research report dated April 10, 2018....

Buy Aurobindo Pharma; target of Rs 909: Prabhudas Lilladher

4.40 pm | 09 Feb 2018 |  Source: Moneycontrol.com

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 909 in its research report dated ...

Aurobindo Pharma may post 18% growth in Q3 profit, US business seen up 12%

12.28 pm | 07 Feb 2018 |  Source: CNBC-TV18

Europe and Rest of World sales are likely to grow 15-18 percent YoY while API business is likely to be flat....

1 2
Quick Links for Aurobindo Pharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.